Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Carcinomas of the salivary glands (SGCs) are rare tumors. Some selected salivary gland
histotypes such as salivary duct carcinomas (SDC) and adenocarcinomas, NOS (not otherwise
specified) distinguish themselves for the expression of androgen receptors (AR), which is
reported in 21% to 43% of the cases. Thus, similarly to prostate cancer (Pca), androgen
deprivation therapy (ADT) has been suggested to be beneficial in patients with recurrent or
disseminated AR-expressing disease. No other therapy except palliative chemotherapy is
available after progression on ADT, thus underling the necessity of alternative therapeutic
approaches.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano